Pramlintide vs PT-141
A neutral, side-by-side comparison of two metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Pramlintide
Synthetic amylin analogue (Symlin) approved as an adjunct to insulin for both type 1 and type 2 diabetes. Amylin is normally co-secreted with insulin from pancreatic beta cells, but is deficient in T1D (beta cell destruction) and reduced in T2D. Pramlintide replaces this missing signal to reduce post-meal glucose spikes and food intake.
Full profilePT-141
PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts centrally on the nervous system rather than peripherally, distinguishing it mechanistically from PDE5 inhibitors like sildenafil.
Full profile| Pramlintide | PT-141 | |
|---|---|---|
| Category | Metabolic | Metabolic |
| Also known as | Symlin, AC137, synthetic amylin | Bremelanotide, Vyleesi, Melanocortin receptor agonist |
| Evidence | FDA-approved | FDA-approved |
| Dosing range | 15mcg–120mcg mcg, Before major meals (3x daily) | 0.5mg–2mg mg, as needed, 45 minutes before activity (max 1x per 24h) |
| Administration | Subcutaneous injection | Subcutaneous injection, Intranasal (historical — discontinued due to BP concerns) |
| Key side effects | Nausea (most common, often transient in first 4 weeks), Hypoglycemia risk (when combined with insulin — insulin dose reduction required), Vomiting, Decreased appetite | Nausea (most common — ~40% in trials), Flushing, Headache, Transient blood pressure elevation |
| Cited sources | 2 references | 1 reference |
Key differences
- Administration: Pramlintide — Subcutaneous injection; PT-141 — Subcutaneous injection, Intranasal (historical — discontinued due to BP concerns).
- Dosing units differ: Pramlintide is dosed in mcg, PT-141 in mg — they operate at different scales.
- Frequency: Pramlintide is typically Before major meals (3x daily); PT-141 is as needed, 45 minutes before activity (max 1x per 24h).
- Research depth: this profile cites 2 sources for Pramlintide vs 1 for PT-141.
How each works
Pramlintide
Pramlintide reduces post-prandial glucose by three complementary mechanisms: slowing gastric emptying, suppressing post-meal glucagon secretion from alpha cells, and signaling meal-related satiety via brainstem amylin receptors. Phase 3 trials in both T1D and T2D demonstrated HbA1c reductions of 0.3–0.5% when added to insulin, with additional weight loss of 1–3kg — a welcome effect contrasting with insulin's typical weight gain.
PT-141
PT-141 activates MC3R and MC4R receptors in the hypothalamus, triggering downstream sexual arousal pathways independent of vascular effects. Phase 3 trials supporting Vyleesi approval showed statistically significant improvements in desire and reductions in distress in women with HSDD. Off-label research explores use in men with erectile dysfunction refractory to PDE5 inhibitors.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.